<DOC>
	<DOC>NCT01047345</DOC>
	<brief_summary>This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™. Participants will receive vaccination with 9vHPV vaccine or placebo on Day 1, Month 2, and Month 6 of the Base Study. Participants who receive placebo in the Base Study will be eligible to receive vaccination with 9vHPV vaccine on Day 1, Month 2, and Month 6 of the Extension Study.</brief_summary>
	<brief_title>A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participants Age 12 to 15 Years: Participant is in good health Parent/legal guardian and participant agree to provide study personnel with a primary telephone number for followup Participant received a 3dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1 Participant has not received any other HPV vaccine Participant is not yet sexually active Participants Age 16 to 26 Years: Participant is in good health Participant agrees to provide a primary telephone number for followup Participant received a 3dose regimen of marketed GARDASIL™ within a 1 year period and the last dose of GARDASIL™ was at least 1 year from study day 1 Participant has not received any other HPV vaccine Participant has never had Papanicolaou (Pap) testing or has only had normal results Participant has a history of 0 to 4 lifetime sexual partners at enrollment All participants: Participant has a history of severe allergic reaction that required medical intervention Participant has any disorder that would contraindicate intramuscular injections Participant is pregnant Participant is immunocompromised or has an autoimmune condition Participant has had a splenectomy Participant has received any immune globulin product or bloodderived product Participant has participated in a HPV vaccine clinical trial Participants Age 16 to 26 Only: Participant expects to donate eggs during the study Participant has a history of abnormal cervical biopsy result Participant has a history of HPVrelated external genital lesions, external genital cancer, HPVrelated vaginal lesions, or vaginal cancer</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cervical cancer</keyword>
	<keyword>Genital warts</keyword>
	<keyword>Human papillomavirus vaccine</keyword>
	<keyword>GARDASIL™</keyword>
</DOC>